CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy

(2019) Jianguang Zhang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy

(2019) Fernando Souza-Fonseca-Guimaraes et al.   TRENDS IN IMMUNOLOGY

Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy

(2019) Tahir B. Dar et al.   Frontiers in Immunology

Turning “Cold” Into “Hot” Tumors—Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers

(2019) Lisa Sevenich   Frontiers in Oncology

Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy

(2019) Rami El Assal et al.   Advanced Science

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

(2019) Stephanie L. Goff et al.   JOURNAL OF IMMUNOTHERAPY

Genetically engineered CAR NK cells display selective cytotoxicity against FLT3‐positive B‐ALL and inhibit in vivo leukemia growth

(2019) Sarah Oelsner et al.   INTERNATIONAL JOURNAL OF CANCER

Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer–Based “Off-the-Shelf” Acute Myeloid Leukemia Immunotherapies

(2019) Stephan Kloess et al.   HUMAN GENE THERAPY

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

(2019) William Tomaszewski et al.   CLINICAL CANCER RESEARCH

3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids

(2019) Theresa E Schnalzger et al.   EMBO JOURNAL

CAR T cells for brain tumors: Lessons learned and road ahead

(2019) David Akhavan et al.   IMMUNOLOGICAL REVIEWS

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

(2019) Bryan D. Choi et al.   NATURE BIOTECHNOLOGY

Mechanisms of immunotherapy resistance: lessons from glioblastoma

(2019) Christopher M. Jackson et al.   NATURE IMMUNOLOGY

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers

(2019) Janakiraman Subramanian et al.   ONCOLOGIST

EGFR and mTOR as therapeutic targets in glioblastoma

(2019) Michael W. Ronellenfitsch et al.   Oncotarget

Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma

(2019) Chen Zhu et al.   OncoImmunology

Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival

(2019) Andrea Gras Navarro et al.   Cancers

Preservation of cell-based immunotherapies for clinical trials

(2019) RUI LI et al.   CYTOTHERAPY

Functional morphology of the blood–brain barrier in health and disease

(2018) Stefan Liebner et al.   ACTA NEUROPATHOLOGICA

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

(2018) Ye Li et al.   Cell Stem Cell

CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

(2018) Brooke L. Prinzing et al.   Expert Review of Anticancer Therapy

Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells

(2018) Bian Hu et al.   HUMAN GENE THERAPY

When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma

(2018) Saskia Roesch et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma

(2018) Daniel Dubinski et al.   JOURNAL OF NEURO-ONCOLOGY

Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma

(2018) Katarzyna C. Pituch et al.   MOLECULAR THERAPY

Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma

(2018) Christine E. Brown et al.   MOLECULAR THERAPY

Current state of immunotherapy for glioblastoma

(2018) Michael Lim et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

(2018) Zhenyi An et al.   ONCOGENE

Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy

(2018) Serena Pellegatta et al.   Science Translational Medicine

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

(2018) Rohtesh S. Mehta et al.   Frontiers in Immunology

In Search for Reliable Markers of Glioma-Induced Polarization of Microglia

(2018) Kacper A. Walentynowicz et al.   Frontiers in Immunology

Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors–Human Leukocyte Antigen Ligand Mismatch and Activation Receptor–Ligand Interactions

(2018) Heleen Neeltje Haspels et al.   Frontiers in Immunology

Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide

(2018) Serena Pellegatta et al.   OncoImmunology

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

(2018) Yao Wang et al.   OncoImmunology

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

(2018) Zhongzhen Yi et al.   Molecular Therapy-Methods & Clinical Development

Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells

(2018) TOSHIHARU MURAKAMI et al.   ANTICANCER RESEARCH

Pan-cancer deconvolution of tumour composition using DNA methylation

(2018) Ankur Chakravarthy et al.   Nature Communications

Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bi-targeted Chimeric Antigen Receptor T Cell

(2018) Hua Jiang et al.   Cancer Immunology Research

Checkpoint blockade reverses anergy in IL13Rα2 humanized scFv based CAR T cells to treat murine and canine gliomas.

(2018) Yibo Yin et al.   Molecular Therapy-Oncolytics

Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas

(2018) Pia S. Zeiner et al.   BRAIN PATHOLOGY

Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors

(2018) Giulia Golinelli et al.   CANCER GENE THERAPY

­­­­Immunotherapy for Glioblastoma: Adoptive T-cell Strategies

(2018) Bryan D. Choi et al.   CLINICAL CANCER RESEARCH

Receptor-Targeted Glial Brain Tumor Therapies

(2018) Puja Sharma et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

NK Cell-Based Glioblastoma Immunotherapy

(2018) Irene Golán et al.   Cancers

Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor–Based Immunotherapy and Chemotherapy

(2017) Rüdiger Klapdor et al.   HUMAN GENE THERAPY

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

(2017) E Liu et al.   LEUKEMIA

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

(2017) Kevin Bielamowicz et al.   NEURO-ONCOLOGY

CD70, a novel target of CAR T-cell therapy for gliomas

(2017) Linchun Jin et al.   NEURO-ONCOLOGY

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme

(2017) Jennifer P. Newman et al.   Nature Communications

A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy

(2017) Brent A. Williams et al.   Oncotarget

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants

(2017) Giedre Krenciute et al.   Cancer Immunology Research

Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation

(2017) Markus Granzin et al.   Frontiers in Immunology

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

(2017) John P. Veluchamy et al.   Frontiers in Immunology

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

(2017) Congcong Zhang et al.   Frontiers in Immunology

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients

(2016) Mev Dominguez–Valentin et al.   CANCER RESEARCH

Expanded and armed natural killer cells for cancer treatment

(2016) Noriko Shimasaki et al.   CYTOTHERAPY

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

(2016) Meenakshi Hegde et al.   JOURNAL OF CLINICAL INVESTIGATION

Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma

(2016) Giedre Krenciute et al.   MOLECULAR THERAPY

P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

(2016) M. C. Burger et al.   NEURO-ONCOLOGY

Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival

(2016) Ryan Alkins et al.   NEURO-ONCOLOGY

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

(2016) Sébastien Viel et al.   Science Signaling

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

(2016) Caroline Jochems et al.   Oncotarget

Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies

(2016) Robert L. Bowman et al.   Cell Reports

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

(2016) Sébastien Viel et al.   Science Signaling

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G

(2016) Sareetha Kailayangiri et al.   OncoImmunology

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma

(2015) Diana Seidel et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy

(2015) Garnet Suck et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Natural Killer Cell Adoptive Transfer Therapy

(2015) Zachary B. Davis et al.   CANCER JOURNAL

Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

(2015) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

(2015) A. Scholz et al.   EMBO Molecular Medicine

Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model

(2015) Dimitrios Mathios et al.   INTERNATIONAL JOURNAL OF CANCER

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma

(2015) Nadja Müller et al.   JOURNAL OF IMMUNOTHERAPY

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

(2015) Congcong Zhang et al.   JNCI-Journal of the National Cancer Institute

Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor

(2015) Kurt Schönfeld et al.   MOLECULAR THERAPY

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

(2015) Laura A. Johnson et al.   Science Translational Medicine

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

(2015) Congcong Zhang et al.   JNCI-Journal of the National Cancer Institute

Advantages and applications of CAR-expressing natural killer cells

(2015) Wolfgang Glienke et al.   Frontiers in Pharmacology

The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer

(2015) Katayoun Rezvani et al.   Frontiers in Immunology

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

(2015) Sabrina Genßler et al.   OncoImmunology

Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57

(2015) Xuekai Zhu et al.   Oncotarget

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

(2015) Jianfeng Han et al.   Scientific Reports

Epidemiologic and Molecular Prognostic Review of Glioblastoma

(2014) J. P. Thakkar et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

T cells redirected to interleukin-13Rα2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1

(2014) Simone Krebs et al.   CYTOTHERAPY

NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival

(2014) Andrea Gras Navarro et al.   JOURNAL OF IMMUNOLOGY

Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients

(2014) Lin-Fang Wang et al.   ONCOLOGY REPORTS

Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma

(2014) Justyna Kmiecik et al.   OncoImmunology

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells

(2014) Rachel E Beard et al.   Journal for ImmunoTherapy of Cancer

Focused Ultrasound Delivers Targeted Immune Cells to Metastatic Brain Tumors

(2013) R. Alkins et al.   CANCER RESEARCH

Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class

(2013) W. C. Rutledge et al.   CLINICAL CANCER RESEARCH

EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

(2013) J. H. Sampson et al.   CLINICAL CANCER RESEARCH

T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo

(2013) C. Geldres et al.   CLINICAL CANCER RESEARCH

Treatment of patients with advanced cancer with the natural killer cell line NK-92

(2013) Torsten Tonn et al.   CYTOTHERAPY

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma

(2013) Bryan D. Choi et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma

(2013) Chan-Juan Shen et al.   Journal of Hematology & Oncology

Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma

(2013) Meenakshi Hegde et al.   MOLECULAR THERAPY

Activating natural cytotoxicity receptors of natural killer cells in cancer and infection

(2013) Joachim Koch et al.   TRENDS IN IMMUNOLOGY

Bringing natural killer cells to the clinic: ex vivo manipulation

(2013) R. W. Childs et al.   Hematology-American Society of Hematology Education Program

Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

(2013) Masasuke Ohno et al.   Journal for ImmunoTherapy of Cancer

Adoptive Cell Therapies for Glioblastoma

(2013) Kevin Bielamowicz et al.   Frontiers in Oncology

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

(2012) Christiane Sahm et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells

(2012) S. Kong et al.   CLINICAL CANCER RESEARCH

Stem-like Tumor-Initiating Cells Isolated from IL13R 2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine-Redirected T Cells

(2012) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

(2012) Richard A. Morgan et al.   HUMAN GENE THERAPY

T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma

(2012) Kevin KH Chow et al.   MOLECULAR THERAPY

Human Glioblastoma Stem-Like Cells are More Sensitive to Allogeneic NK and T Cell-Mediated Killing Compared with Serum-Cultured Glioblastoma Cells

(2011) Tony Avril et al.   BRAIN PATHOLOGY

NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin

(2011) Ruth Esser et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology

(2011) Isaac Yang et al.   JOURNAL OF NEUROSURGERY

TGF-  downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

(2011) C. A. Crane et al.   NEURO-ONCOLOGY

HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors

(2010) N. Ahmed et al.   CLINICAL CANCER RESEARCH

Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response

(2010) C Hartmann et al.   ONCOGENE

2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells

(2009) B. Altvater et al.   CLINICAL CANCER RESEARCH

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties

(2009) R. Castriconi et al.   JOURNAL OF IMMUNOLOGY

Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma

(2009) Robert Owen Dillman et al.   JOURNAL OF IMMUNOTHERAPY

Very late relapses in glioblastoma long-term survivors

(2009) Oliver Bähr et al.   JOURNAL OF NEUROLOGY

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY

DAP10- and DAP12-associated receptors in innate immunity

(2008) Lewis L. Lanier   IMMUNOLOGICAL REVIEWS